Tower Research Capital LLC (Trc) Galectin Therapeutics Inc Transaction History

Tower Research Capital LLC (Trc)

$4.87 Billion
Q4 2024

A detailed history of Tower Research Capital LLC (Trc) transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 7,623 shares of GALT stock, worth $11,205. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,623

Previous 3,265 133.48%

Holding current value

$11,205

Previous $8,000 12.5%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$0.87 - $3.0 $3,791 - $13,074	4,358 Added 133.48%	7,623 $9,000
Q3 2024 Nov 14, 2024	SELL	$2.04 - $2.86 $2,372 - $3,326	-1,163 Reduced 26.26%	3,265 $8,000
Q2 2024 Aug 13, 2024	SELL	$2.13 - $4.2 $2,536 - $5,002	-1,191 Reduced 21.2%	4,428 $10,000
Q1 2024 May 15, 2024	SELL	$1.6 - $2.44 $2,796 - $4,265	-1,748 Reduced 23.73%	5,619 $13,000
Q4 2023 Feb 13, 2024	SELL	$1.6 - $2.18 $9,742 - $13,274	-6,089 Reduced 45.25%	7,367 $12,000
Q3 2023 Nov 14, 2023	BUY	$1.38 - $1.97 $6,597 - $9,418	4,781 Added 55.11%	13,456 $25,000
Q2 2023 Aug 14, 2023	BUY	$1.32 - $2.08 $3,241 - $5,108	2,456 Added 39.49%	8,675 $12,000
Q1 2023 May 09, 2023	SELL	$1.1 - $2.4 $6,492 - $14,164	-5,902 Reduced 48.69%	6,219 $13,000
Q4 2022 Feb 10, 2023	BUY	$1.03 - $1.66 $4,882 - $7,868	4,740 Added 64.22%	12,121 $14,000
Q3 2022 Nov 10, 2022	BUY	$1.31 - $2.48 $302 - $572	231 Added 3.23%	7,381 $12,000
Q2 2022 Aug 15, 2022	BUY	$1.19 - $1.74 $5,596 - $8,183	4,703 Added 192.19%	7,150 $9,000
Q1 2022 May 12, 2022	SELL	$1.61 - $2.31 $11,173 - $16,031	-6,940 Reduced 73.93%	2,447 $4,000
Q4 2021 Feb 14, 2022	BUY	$2.07 - $3.8 $13,069 - $23,993	6,314 Added 205.47%	9,387 $19,000
Q3 2021 Nov 15, 2021	SELL	$2.59 - $4.15 $18,464 - $29,585	-7,129 Reduced 69.88%	3,073 $12,000
Q2 2021 Aug 16, 2021	BUY	$2.07 - $5.1 $10,635 - $26,203	5,138 Added 101.46%	10,202 $33,000
Q1 2021 May 17, 2021	SELL	$1.96 - $2.57 $22,757 - $29,840	-11,611 Reduced 69.63%	5,064 $11,000
Q4 2020 Feb 16, 2021	SELL	$2.24 - $2.87 $58,667 - $75,168	-26,191 Reduced 61.1%	16,675 $37,000
Q3 2020 Nov 16, 2020	BUY	$2.53 - $3.64 $86,789 - $124,866	34,304 Added 400.65%	42,866 $114,000
Q2 2020 Aug 13, 2020	BUY	$1.66 - $3.15 $10,662 - $20,232	6,423 Added 300.28%	8,562 $26,000
Q1 2020 May 15, 2020	BUY	$1.51 - $3.0 $3,229 - $6,417	2,139 New	2,139 $4,000
Q4 2019 Feb 07, 2020	SELL	$2.79 - $4.32 $2,728 - $4,224	-978 Closed	0 $0
Q3 2019 Nov 05, 2019	SELL	$3.0 - $4.05 $9,165 - $12,372	-3,055 Reduced 75.75%	978 $4,000
Q2 2019 Aug 13, 2019	SELL	$3.61 - $5.0 $12,819 - $17,755	-3,551 Reduced 46.82%	4,033 $17,000
Q1 2019 May 14, 2019	BUY	$3.86 - $6.02 $29,274 - $45,655	7,584 New	7,584 $39,000
Q4 2018 Feb 14, 2019	SELL	$3.43 - $5.74 $28,928 - $48,411	-8,434 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$3.68 - $6.93 $27,011 - $50,866	7,340 Added 670.93%	8,434 $51,000
Q2 2018 Aug 15, 2018	BUY	$3.16 - $9.16 $3,457 - $10,021	1,094 New	1,094 $7,000

Others Institutions Holding GALT

# of Institutions

112

Shares Held

9.93M

Call Options Held

3.78M

Put Options Held

5.27M

View Full List

About GALECTIN THERAPEUTICS INC

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $87.4M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

More about GALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Account

Tower Research Capital LLC (Trc) Galectin Therapeutics Inc Transaction History